Diagnosis of early pre-patent schistosomiasis by cystatin capture enzyme-linked immunosorbent assay.
To test the efficacy of detecting anti-Schistosoma mansoni cysteine proteinase antibodies (CP Abs) by cystatin capture (CC) ELISA in the diagnosis of prepatent schistosomiasis (before egg passing); 253 schistosome negative individuals were selected and divided into two groups. The first comprised 118 children whose first water contact occurred in March and April 1999 (primarily infected), and the second 135 individuals were previously treated for schistosomasis (re-infected). All the individuals were followed up triweekly by stool for detecting schistosome eggs and by serological tests for detecting antibodies against CP and anti-soluble egg antigens (SEA) by ELISA technique. CP seropositivity was detected in 92 from all examined individuals, out of them 38 were primarily infected (PI) children (20 of them were pre-patently treated), the rest; 54 were re-infected patients (28 out of them were pre-patently treated). The untreated (44) individuals from both groups were followed up till they passed eggs within 4 weeks and then were treated (post-patent). CP Abs were reassessed for the 92 patients after treatment, only 11 (12%) were still seropositive with marked decrease in optical density (O.D.) level than before treatment. Anti-SEA IgM Abs were sought in the 92 CP seropositive sera, and the seropositivity rate was lower in 38 PI children (5.3%) than in the 54 re-infected individuals (92.6%). The anti-SEA seropositivity rate in the PI children was 5% in the pre-patent and was 94.4% in the post-patent. None of the 161 CP seronegative individuals passed eggs up to 12 weeks.